The Role of Maintenance/Consolidation Therapy in Multiple Myeloma: A Patient-Centered Approach

Please Log In or Register to continue.

Release Date: November 08, 2017
Expiration Date: November 08, 2018

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Maintaining results of successful induction therapy is an important goal in the treatment of multiple myeloma. Recent advances in maintenance therapy indicate it is a viable approach, resulting in longer progression-free survival and, more importantly, overall survival. Ideally, maintenance therapy should sustain treatment responses, have good safety and tolerability profiles in long-term use, and be convenient for patients. Join Dr. Laubach as he navigates through a series of case presentations to provide you with the latest evidence and advances in clinical research to consider in this patient population.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify patients who may benefit from maintenance and consolidation therapy
  • Summarize treatment options available based on individual patient profile and treatment history
  • Summarize data from recent clinical trials related to patient outcomes


The Role of Maintenance/Consolidation Therapy in Multiple Myeloma: A Patient-Centered Approach – Jacob Laubach, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 8, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Jacob Laubach, MD
Assistant Professor in Medicine
Harvard Medical School
Clinical Director of the Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Jacob Laubach completed his medical degree, residency, and fellowship in hematology at Duke University Medical Center in Durham, North Carolina. He is an Assistant Professor in Medicine at Harvard Medical School, and the Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston.

Since joining the Dana-Farber Cancer Institute faculty, Dr. Laubach has dedicated himself to the growth and expansion of the multiple myeloma clinical program and the advancement of clinical research evaluating new therapeutic agents in multiple myeloma. As a clinician, he has developed a large academic practice focused on the care of patients with plasma cell disorders, including multiple myeloma, AL amyloidosis, POEMS syndrome, and cryoglobulinemia. As a clinical investigator, his research has focused primarily on the development of new therapeutic agents. Dr. Laubach has been integrally involved in the study of histone deacetylase inhibition as a treatment strategy in multiple myeloma and in the development of monoclonal antibodies targeting myeloma tumor cell epitopes such as CS-1 (elotuzumab) and CD38 (daratumumab).


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-171-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Jacob Laubach has received honoraria as a consultant from Celgene Corporation, Novartis AG, Onyx, and Takeda Oncology.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.